Known targets — ChEMBL curated mechanism
MMP1MMP13MMP7MMP8polrplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Cyclopropane. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Alcohol SCHEMBL5933717 | 1.00 | — | — | |
| Alcohol SCHEMBL27972143 | 1.00 | ALDH1A1 (0.67) | — | |
| Cyclopentane SCHEMBL9633004 | 1.00 | ALDH1A1 (0.67) | — | |
| Cyclohexane SCHEMBL12482623 | 1.00 | ALDH1A1 (0.67) | — | |
| Cycloheptane SCHEMBL14721149 | 1.00 | ALDH1A1 (0.67) | — | |
| Cyclopropane SCHEMBL322401 | 1.00 | — | — | |
| Alcohol SCHEMBL3968617 | 1.00 | ALDH1A1 (0.67) | — | |
| Cyclohexane SCHEMBL9633835 | 1.00 | ALDH1A1 (0.67) | — | |
| Cyclohexane SCHEMBL959934 | 1.00 | — | — | |
| Cyclopentane SCHEMBL5158267 | 1.00 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-2011529503-A | — | — | 2011-12-08 | — | — | JP | claimed |
| EP-2328572-A1 | PKC-ACTIVATING COMPOUNDS FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | Blanchette Rockefeller Neurosciences Institute (US) | 2011-06-08 | — | — | EP | claimed |
| WO-2010014585-A1 | PKC-ACTIVATING COMPOUNDS FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | BLANCHETTE ROCKEFELLER NEUROSCIENCES INSTITUTE (US) | 2010-02-04 | — | — | WO | claimed |